Transplant Rejection Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Transplant Rejection stocks.

Transplant Rejection Stocks Recent News

Date Stock Title
May 17 BMY AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
May 17 ALKS The Bottom Fishing Club: Alkermes Has Great Value And Safety
May 17 BMY The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
May 17 BMY Erasca restructures; Novartis moves to complete MorphoSys deal
May 17 BMY BMS reports four-year data from psoriasis treatment extension trial
May 16 CDNA Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
May 16 BMY Walmart Earnings & the State of the Consumer
May 16 BMY Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
May 16 BMY New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
May 16 BMY Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
May 16 BMY FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
May 16 BMY Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
May 15 BMY Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
May 15 BMY Tudor Investment's top buys and sells in Q1
May 15 BMY Bristol Myers' Breyanzi gains additional indication for follicular lymphoma
May 15 BMY UPDATE 3-US FDA approves expanded use of Bristol Myers' cancer cell therapy
May 14 ALKS Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
May 13 CDNA CareDx cut to market perform by Raymond James over valuation
May 13 BMY Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
May 13 BMY One stock is dragging down the S&P 500's earnings growth
Transplant Rejection

Transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Transplant rejection can be lessened by determining the molecular similitude between donor and recipient and by use of immunosuppressant drugs after transplant.

Browse All Tags